Literature DB >> 9835651

Protein phosphatase type 1, the product of the retinoblastoma susceptibility gene, and cell cycle control.

E Rubin1, S Tamrakar, J W Ludlow.   

Abstract

Cell cycle regulation--three words which conjure in the minds of those conducting research in this area a myriad of proteins and biochemical pathways. In this examination, an overview of the mammalian cell cycle is presented with emphasis on the function of the negative growth regulatory protein, the product of the retinoblastoma susceptibility gene, pRb. Since the activity of this protein itself is regulated by phosphorylation on serine and threonine residues, more elaborate discussions on the enzymes involved in placing the phosphates on, and taking them off, are provided. The focus here is on the activity of the members of the type 1 class of serine/threonine phosphatases. More specifically, the role of PP1 in regulating cell cycle progression by dephosphorylating pRb during mitosis, thereby activating the growth suppressing function of pRb, is presented. Suggested avenues for further investigation regarding the functional significance, and ultimately the effect on cell cycle progression, of the complex between pRb and the type 1 phosphatases are also discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9835651     DOI: 10.2741/a357

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  11 in total

1.  Uncoupling between phenotypic senescence and cell cycle arrest in aging p21-deficient fibroblasts.

Authors:  V Dulić; G E Beney; G Frebourg; L F Drullinger; G H Stein
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  Inhibition of S-phase progression by adeno-associated virus Rep78 protein is mediated by hypophosphorylated pRb.

Authors:  P Saudan; J Vlach; P Beard
Journal:  EMBO J       Date:  2000-08-15       Impact factor: 11.598

Review 3.  Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer.

Authors:  Ronald C Bruntz; Craig W Lindsley; H Alex Brown
Journal:  Pharmacol Rev       Date:  2014-10       Impact factor: 25.468

Review 4.  Regulation of Cardiac PKA Signaling by cAMP and Oxidants.

Authors:  Friederike Cuello; Friedrich W Herberg; Konstantina Stathopoulou; Philipp Henning; Simon Diering
Journal:  Antioxidants (Basel)       Date:  2021-04-24

5.  Characterization of the p53 response to oncogene-induced senescence.

Authors:  Lidia Ruiz; Magali Traskine; Irene Ferrer; Estrella Castro; Juan F M Leal; Marcelline Kaufman; Amancio Carnero
Journal:  PLoS One       Date:  2008-09-18       Impact factor: 3.240

6.  Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer.

Authors:  Eva M Verdugo-Sivianes; Lola Navas; Sonia Molina-Pinelo; Irene Ferrer; Alvaro Quintanal-Villalonga; Javier Peinado; Jose M Garcia-Heredia; Blanca Felipe-Abrio; Sandra Muñoz-Galvan; Juan J Marin; Luis Montuenga; Luis Paz-Ares; Amancio Carnero
Journal:  Oncotarget       Date:  2017-10-26

Review 7.  Role of the Holoenzyme PP1-SPN in the Dephosphorylation of the RB Family of Tumor Suppressors During Cell Cycle.

Authors:  Eva M Verdugo-Sivianes; Amancio Carnero
Journal:  Cancers (Basel)       Date:  2021-05-06       Impact factor: 6.639

8.  Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma.

Authors:  A Aigelsreiter; A L Ress; K Bettermann; S Schauer; K Koller; F Eisner; T Kiesslich; T Stojakovic; H Samonigg; P Kornprat; C Lackner; J Haybaeck; M Pichler
Journal:  Br J Cancer       Date:  2013-04-16       Impact factor: 7.640

9.  Assessing uncertainty in model parameters based on sparse and noisy experimental data.

Authors:  Noriko Hiroi; Maciej Swat; Akira Funahashi
Journal:  Front Physiol       Date:  2014-04-04       Impact factor: 4.566

Review 10.  Marine Sponge Natural Products with Anticancer Potential: An Updated Review.

Authors:  Cinzia Calcabrini; Elena Catanzaro; Anupam Bishayee; Eleonora Turrini; Carmela Fimognari
Journal:  Mar Drugs       Date:  2017-10-13       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.